A drug discovery company dedicated to developing treatments for Neurofibromatosis Type 1

iNFixion Bioscience is currently seeking scientific collaboration and investment opportunities. Please reach out to our team at info@infixionbio.com to schedule an initial meeting.

Grant & Funding Partners

iNFixion Bioscience has received 7 peer-reviewed grants from the NIH, DoD, and NF foundations.

 

Infixion updates

Company Newsletters

Infixion updates

Latest News

iNFixion Bioscience announced ongoing collaborations with individual researchers from the University of Arizona, the University of Alabama Huntsville, and the Broad Institute in order to build tools to study NF1 haploinsufficiency.  These projects include developing machine learning models to identify compounds impacting NF1 gene expression and the development of synthetic transcription factors to specifically increase NF1 protein expression during in vitro experimentation.  These efforts are being supported in part by grants from NF Northeast and NF North Central, both regional members of NF Network, a national organization advocating for and supporting individuals and families impacted by neurofibromatosis.

Thank you to the Giorgio Foundation and Stapelfeld family for their generous support

We are deeply grateful to the Giorgio Foundation and Stapelfeld family for their generous support of iNFixion Bioscience. Their partnership helps fuel our mission to develop new therapies that restore healthy NF1 protein (neurofibromin) to treat and prevent symptoms of neurofibromatosis type...

iNFixion team attends 2025 NF Conference in Washington, DC

Members of the iNFixion Bioscience team recently attended the 2025 NF Conference in Washington, DC, hosted by the Children’s Tumor Foundation. As scientists and NF1 parents, we are deeply grateful for the opportunity to connect with collaborators, learn from others...

New video by WCB films describing NF1 and iNFixion’s unique approach to treat the root cause

In this new company video, we share our vision of developing treatments that target the root cause of NF1. Thanks to Savanna for sharing her story, to our advisors and collaborators for their support, and to the team at WCB...

NYC Reception to support iNFixion, generously hosted by the Kaufelt Family in partnership with Penny’s Flight Foundation

Thank you to the Kaufelt family, in partnership with Penny’s Flight Foundation, for hosting a meaningful evening in support of iNFixion Bioscience and our mission to develop breakthrough treatments for NF1. The event brought together a passionate community of supporters...

iNFixion team attends Gilbert Family Foundation meeting focused on NF1 preclinical models

iNFixion  recently attended its first Gilbert Family Foundation (GFF) meeting where the team learned about many new NF1 preclinical models, including rodent models and organoid models, that are being developed with funding from the GFF. iNFixion’s Medical Director, Dr. Mick...

With promising in vitro data utilizing ASOs to boost NF1 expression, iNFixon launches seed financing round to fund in vivo animal studies

iNFixion Bioscience is developing an antisense oligonucleotide (ASO) therapy designed to boost NF1 protein expression, aiming to address the underlying root cause driver of neurofibromatosis type 1 (NF1) symptoms, namely NF1 protein haploinsufficiency. Following promising in vitro data, demonstrating the...

iNFixion CEO presents at the Invest in Cures Forum in San Diego, CA

iNFixion CEO, Herb Sarnoff, was featured in the Translational Research Showcase of the Invest in Cures Forum where he shared the personal motivation behind founding iNFixion Bioscience and the company’s ongoing efforts develop a therapy to address the unmet needs...

iNFixion CEO and investors attend NF advocacy event in DC with NF Network

Herb Sarnoff, CEO of iNFixion, along with several company investors joined forces in support of the Neurofibromatosis Network’s annual three-day advocacy trip to Washington, DC. Alongside over 100 NF advocates from across the country, Herb and his team met with...

iNFixion team attends Children’s Tumor Foundation Global NF Conference in Brussels

Members of iNFixion’s executive team headed to Brussels for the 2024 Global NF Conference, the leading international meeting shaping the future of neurofibromatosis and schwannomatosis research and clinical care. Organized by the Children’s Tumor Foundation and the European NF Group,...

iNFixion is awarded Gilbert Family Foundation grant to generate new NF1 preclinical models focused on neurocognition

The Gilbert Family Foundation has awarded a three-year grant to iNFixion Bioscience as part of its Next Generation Neurofibromatosis Models Initiative to develop a more human-translatable rodent model for the cognitive and learning deficits experienced by individuals with NF1.  This...

iNFixion Bioscience published peer-reviewed paper on haploinsufficiency correction therapy for NF1

iNFixion published a peer-reviewed paper in the Journal of Translational Genetics and Genomics highlighting the rationale for haploinsufficiency correction therapy (HCT) as a potential treatment for neurofibromatosis type 1 (NF1). Evidence supports that a reduced level of functional neurofibromin (NF1...

The DOD Neurofibromatosis Research Program awards grant to collaborative project between James Walker’s Lab at MGH and iNFixion Bioscience

A three-year grant through the DOD Neurofibromatosis Research Program (NFRP) has been awarded to Dr. James Walker’s lab at Massachusetts General Hospital (MGH), with iNFixion Bioscience as a sub-awardee, to develop and validate a lentiviral CRISPRa/Cas9 tool designed to enhance...

iNFixion is awarded third NIH SBIR phase 1 grant to develop therapeutics for NF1

iNFixion announced its third NIH SBIR Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS). iNFixion has received two previous NIH SBIR Phase 1 grants for NF1 drug discovery (2020 and 2021), and this third NIH...

iNFixion presents research on new and superior monoclonal antibody for detecting NF1 protein

iNFixion is working to discover a new therapeutic for Neurofibromatosis (NF1) by correcting for the lack of normal NF1 protein (neurofibromin), a problem that happens to people born with a mutation in the NF1 gene. One key tool in measuring...

iNFixion Bioscience announces second NIH SBIR Phase 1 Grant award

iNFixion Bioscience announced today that it had been granted its second NIH Phase 1 SBIR Grant award from the National Institute of Neurological Disorders and Stroke (NINDS).  This 18-month grant, titled “Inhibition of NF1 Protein Degradation as a Treatment for...

iNFixion Bioscience completes NIH I-Corps™ commercialization program

The core team at iNFixion Bioscience has successfully completed the prestigious NIH I-Corps™ commercialization program.  In addition to a commercialization curriculum, the program included teh requirement of conducting interviews with over 100 people from across the NF1 and Rare Drug...

iNFixion awarded NIH SBIR grant; Enters JLABS Accelerator; Hires PhD Researcher

Infixion Bioscience announces it has designed and validated a new monoclonal antibody against NF1 protein. This new NF1-specific reagent is proving to be mInfixion Bioscience announces it has designed and validated a new monoclonal antibody against NF1 protein. This new...

iNFixion Bioscience announces effort to develop new NF1 monoclonal antibody

iNFixion Bioscience announced today its commitment to developing a new monoclonal antibody against NF1 protein. This NF1-specific reagent will be developed in rabbits using full-length NF1 protein as the immunogen, with the program goal being to establish a more sensitive...

iNFixion Bioscience establishes collaboration with University of Wisconsin

The University of Wisconsin Biotechnology Center (UWBC) and iNFixion Bioscience have launched a multi-year collaboration to execute assay development and library screening focused on identifying small molecule NF1 transcriptional regulators.

iNFixion Bioscience launches building of tools to help study NF1 haploinsufficiency

iNFixion Bioscience announced ongoing collaborations with individual researchers from the University of Arizona, the University of Alabama Huntsville, and the Broad Institute in order to build tools to study NF1 haploinsufficiency.  These projects include developing machine learning models to identify...

Ⓒ iNFixion Bioscience (2017-2025). All rights reserved.